

Arturo Sala

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3756185/publications.pdf>

Version: 2024-02-01

53
papers

2,121
citations

201674

27
h-index

233421

45
g-index

55
all docs

55
docs citations

55
times ranked

2565
citing authors

#	ARTICLE	IF	CITATIONS
1	B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. <i>European Journal of Cancer</i> , 2005, 41, 2479-2484.	2.8	136
2	Essential Requirement of Apolipoprotein J (Clusterin) Signaling for I κ B Expression and Regulation of NF- κ B Activity. <i>Journal of Biological Chemistry</i> , 2003, 278, 38214-38219.	3.4	121
3	Poly(ADP-ribose) Polymerase Is a B-MYB Coactivator. <i>Journal of Biological Chemistry</i> , 2000, 275, 10692-10696.	3.4	117
4	Direct Transactivation of the Anti-apoptotic Gene Apolipoprotein J (Clusterin) by B-MYB. <i>Journal of Biological Chemistry</i> , 2000, 275, 21055-21060.	3.4	106
5	Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1994, 91, 10079-10083.	7.1	104
6	Regulation of BALB/c 3T3 fibroblast proliferation by B-myb is accompanied by selective activation of cdc2 and cyclin D1 expression.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1992, 89, 10415-10419.	7.1	103
7	Activation of human B-MYB by cyclins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1997, 94, 532-536.	7.1	98
8	Clusterin, a Haploinsufficient Tumor Suppressor Gene in Neuroblastomas. <i>Journal of the National Cancer Institute</i> , 2009, 101, 663-677.	6.3	87
9	MYB oncoproteins: emerging players and potential therapeutic targets in human cancer. <i>Oncogenesis</i> , 2021, 10, 19.	4.9	79
10	Physical Interaction between MYCN Oncogene and Polycomb Repressive Complex 2 (PRC2) in Neuroblastoma. <i>Journal of Biological Chemistry</i> , 2013, 288, 8332-8341.	3.4	77
11	Polyphenol E Enhances the Antitumor Immune Response in Neuroblastoma by Inactivating Myeloid Suppressor Cells. <i>Clinical Cancer Research</i> , 2013, 19, 1116-1125.	7.0	74
12	Frizzled receptor 6 marks rare, highly tumorigenic stem-like cells in mouse and human neuroblastomas. <i>Oncotarget</i> , 2011, 2, 976-983.	1.8	68
13	Functional and prognostic significance of the genomic amplification of frizzled 6 (<i>FZD6</i>) in breast cancer. <i>Journal of Pathology</i> , 2017, 241, 350-361.	4.5	66
14	B-Myb protein in cellular proliferation, transcription control, and cancer: Latest developments. <i>Journal of Cellular Physiology</i> , 1999, 179, 245-250.	4.1	65
15	Requirement of B- myb Function for Survival and Differentiative Potential of Human Neuroblastoma Cells. <i>Journal of Biological Chemistry</i> , 1995, 270, 8540-8545.	3.4	63
16	B-myb Promotes S Phase and Is a Downstream Target of the Negative Regulator p107 in Human Cells. <i>Journal of Biological Chemistry</i> , 1996, 271, 9363-9367.	3.4	45
17	The Retinoblastoma Family Member p107 Binds to B-MYB and Suppresses Its Autoregulatory Activity. <i>Journal of Biological Chemistry</i> , 1996, 271, 28738-28740.	3.4	44
18	B-MYB transactivates its own promoter through SP1-binding sites. <i>Oncogene</i> , 1999, 18, 1333-1339.	5.9	44

#	ARTICLE	IF	CITATIONS
19	Ca ²⁺ depletion induces nuclear clusterin, a novel effector of apoptosis in immortalized human prostate cells. <i>Cell Death and Differentiation</i> , 2005, 12, 101-104.	11.2	44
20	Physical interaction between CDK9 and B-Myb results in suppression of B-Myb gene autoregulation. <i>Oncogene</i> , 2000, 19, 373-379.	5.9	43
21	Identification and Pharmacological Inactivation of the MYCN Gene Network as a Therapeutic Strategy for Neuroblastic Tumor Cells. <i>Journal of Biological Chemistry</i> , 2015, 290, 2198-2212.	3.4	43
22	Genetic inactivation of ApoJ/clusterin: effects on prostate tumourigenesis and metastatic spread. <i>Oncogene</i> , 2009, 28, 4344-4352.	5.9	42
23	Host humoral and cellular immune mechanisms in the continued suppression of Friend erythroleukemia metastases after interferon alpha/beta treatment in mice.. <i>Journal of Experimental Medicine</i> , 1991, 173, 1193-1203.	8.5	40
24	Regulation of CLU Gene Expression by Oncogenes and Epigenetic Factors. <i>Advances in Cancer Research</i> , 2009, 105, 115-132.	5.0	40
25	The tumour-suppressive function of CLU is explained by its localisation and interaction with HSP60. <i>Cell Death and Disease</i> , 2011, 2, e219-e219.	6.3	37
26	ATR is a MYB regulated gene and potential therapeutic target in adenoid cystic carcinoma. <i>Oncogenesis</i> , 2020, 9, 5.	4.9	37
27	Addiction of MYCN Amplified Tumours to B-MYB Underscores a Reciprocal Regulatory Loop. <i>Oncotarget</i> , 2010, 1, 278-288.	1.8	29
28	PARP co-activates B-MYB through enhanced phosphorylation at cyclin/cdk2 sites. <i>Oncogene</i> , 2001, 20, 8167-8174.	5.9	27
29	Addiction of MYCN amplified tumours to B-MYB underscores a reciprocal regulatory loop. <i>Oncotarget</i> , 2010, 1, 278-88.	1.8	27
30	Temperature-dependent Modification and Activation of B-MYB. <i>Journal of Biological Chemistry</i> , 2005, 280, 15628-15634.	3.4	26
31	B-Myb acts as a repressor of human COL1A1 collagen gene expression by interacting with Sp1 and CBF factors in scleroderma fibroblasts. <i>Biochemical Journal</i> , 2004, 378, 609-616.	3.7	17
32	Hyposialylation of high-molecular-weight membrane glycoproteins parallels the loss of metastatic potential in wheat-germ agglutinin-resistant friend leukemia cells. <i>International Journal of Cancer</i> , 1989, 43, 126-133.	5.1	16
33	c-MYB and TGF β ² : EMT's dynamic duo in breast cancer. <i>Cell Cycle</i> , 2012, 11, 17-17.	2.6	16
34	Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma. <i>Cancers</i> , 2020, 12, 2989.	3.7	16
35	A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. <i>Oncotarget</i> , 2012, 3, 535-545.	1.8	16
36	Generation of a novel Antibody-Drug Conjugate targeting endosialin: potent and durable antitumor response in sarcoma. <i>Oncotarget</i> , 2017, 8, 60368-60377.	1.8	13

#	ARTICLE	IF	CITATIONS
37	Isolation and functional assessment of common, polymorphic variants of the B-MYB proto-oncogene associated with a reduced cancer risk. <i>Oncogene</i> , 2008, 27, 2929-2933.	5.9	12
38	Engineered human mesenchymal stem cells for neuroblastoma therapeutics. <i>Oncology Reports</i> , 2019, 42, 35-42.	2.6	12
39	Integrin-Targeted, Short Interfering RNA Nanocomplexes for Neuroblastoma Tumor-Specific Delivery Achieve MYCN Silencing with Improved Survival. <i>Advanced Functional Materials</i> , 2021, 31, 2104843.	14.9	12
40	B-MYB is hypophosphorylated and resistant to degradation in neuroblastoma: Implications for cell survival. <i>Blood Cells, Molecules, and Diseases</i> , 2007, 39, 263-271.	1.4	11
41	Cutaneous cylindroma: it's all about MYB. <i>Journal of Pathology</i> , 2016, 239, 391-393.	4.5	11
42	Catechins and antitumor immunity. <i>Oncolmmunology</i> , 2013, 2, e24443.	4.6	8
43	A Promyelocytic Leukemia Protein-Thrombospondin-2 Axis and the Risk of Relapse in Neuroblastoma. <i>Clinical Cancer Research</i> , 2016, 22, 3398-3409.	7.0	8
44	Repurposing a psychoactive drug for children with cancer: p27Kip1-dependent inhibition of metastatic neuroblastomas by Prozac. <i>Oncogenesis</i> , 2020, 9, 3.	4.9	5
45	MYC regulates metabolism through vesicular transfer of glycolytic kinases. <i>Open Biology</i> , 2021, 11, 210276.	3.6	5
46	Editorial: Targeting MYCN in Pediatric Cancers. <i>Frontiers in Oncology</i> , 2015, 4, 330.	2.8	4
47	What football can teach science. <i>Nature</i> , 2014, 516, 329-329.	27.8	3
48	DNA damage or growth factor withdrawal does not evoke activation of MYB transcription factors in neuronal cancer cell lines. <i>Neuroscience Letters</i> , 2003, 336, 163-166.	2.1	2
49	Abstract 238: Therapeutic activity of the non-internalizing antibody drug conjugate 1959-sss/DM3 targeting galectin3-binding protein in human neuroblastoma. , 2019, , .		1
50	MYCN Regulates Metabolism Through Vesicular Transfer of Glycolytic Kinases. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
51	A challenge for research in Italy: to raise the dead. <i>Nature</i> , 2001, 414, 581-581.	27.8	0
52	Neuroblastoma: Role of Clusterin as a Tumor Suppressor Gene. <i>Pediatric Cancer</i> , 2012, , 169-176.	0.0	0
53	Abstract 238: Therapeutic activity of the non-internalizing antibody drug conjugate 1959-sss/DM3 targeting galectin3-binding protein in human neuroblastoma. , 2019, , .		0